AccUrine’s BV test kit aids in distinguishing bacterial from viral infections, using a self, rapid urine test.
The Challenge of Diagnosing Acute Respiratory Infections.
Acute respiratory infections are among the most common reasons people seek medical care and receive antibiotics. However, distinguishing between bacterial and viral infections is often difficult due to overlapping symptoms.
Most acute respiratory infections are viral and do not require antibiotics, yet antibiotics are still prescribed in nearly 50% of cases. This overuse accelerates antibiotic resistance, a growing global health crisis responsible for 2.8 million antibiotic-resistant infections and 35,000 deaths annually in the U.S.
AccUrine’s BV test kit is a simple, at-home lateral flow test that uses urine samples to distinguish between bacterial and viral infections—much like the widely used COVID-19 tests. Designed for ease of use, it delivers rapid and reliable results, enabling early diagnosis without the need for specialized equipment or laboratory processing. By facilitating proper treatment decisions, the test helps reduce unnecessary antibiotic use and ensures more targeted care, ultimately leading to better patient outcomes.
Rapid results in under 15 minutes, enabling more confident decisions on antibiotic prescriptions.
Advanced triple-biomarker technology ensures high sensitivity and specificity for accurate differentiation between bacterial and viral infections.
AccUrine’s innovative urine-based proteomic platform enables the early detection and monitoring of systemic inflammation, offering a non-invasive approach to personalized health management.
(Inflammatory Bowel Disease)
With a simple urine test, AccUrine is revolutionizing IBD monitoring, providing patients and physicians with real-time insights into disease sevirity without the need for invasive procedures.
(Congestive Heart Failure)
AccUrine’s advanced at-home monitoring technology enables early detection and continuous assessment of congestive heart failure by reflecting blood biomarker activity through urine, delivering actionable insights that drive better patient outcomes